Literature DB >> 19387437

Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics.

M Bergstrand1, E Söderlind, W Weitschies, M O Karlsson.   

Abstract

Magnetic marker monitoring (MMM) is a new technique for visualizing transit and disintegration of solid oral dosage forms through the gastrointestinal (GI) tract. The aim of this work was to develop a modeling approach for gaining information from MMM studies using data from a food interaction study with felodipine extended-release (ER) formulation. The interrelationship between tablet location in the GI tract, in vivo drug release, and felodipine disposition was modeled. A Markov model was developed to describe the tablet's movement through the GI tract. Tablet location within the GI tract significantly affected drug release and absorption through the gut wall. Food intake decreased the probability of tablet transition from the stomach, decreased the rate with which released felodipine left the stomach, and increased the fraction absorbed across the gut wall. In conclusion, the combined information of tablet location in the GI tract, in vivo drug release, and plasma concentration can be utilized in a mechanistically informative way with integrated modeling of data from MMM studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387437     DOI: 10.1038/clpt.2009.43

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

2.  A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-23       Impact factor: 4.200

3.  A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

Review 4.  Biomagnetic methods: technologies applied to pharmaceutical research.

Authors:  Luciana A Corá; Madileine F Américo; Ricardo B Oliveira; Cristina H R Serra; Oswaldo Baffa; Raul C Evangelista; Giselle F Oliveira; José Ricardo Aruda Miranda
Journal:  Pharm Res       Date:  2010-10-15       Impact factor: 4.200

5.  Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions.

Authors:  Emilie Hénin; Martin Bergstrand; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2015-11-09       Impact factor: 4.200

6.  A Minimal Continuous-Time Markov Pharmacometric Model.

Authors:  Emilie Schindler; Mats O Karlsson
Journal:  AAPS J       Date:  2017-06-20       Impact factor: 4.009

7.  A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.

Authors:  Ahmed Abbas Suleiman; Sebastian Frechen; Matthias Scheffler; Thomas Zander; Lucia Nogova; Martin Kocher; Ulrich Jaehde; Jürgen Wolf; Uwe Fuhr
Journal:  AAPS J       Date:  2015-08-19       Impact factor: 4.009

8.  Population in vitro-in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole.

Authors:  Ahmad Y Abuhelwa; Stuart Mudge; Richard N Upton; David J R Foster
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-17       Impact factor: 2.745

9.  Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.

Authors:  V Pilla Reddy; K J Petersson; A A Suleiman; A Vermeulen; J H Proost; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.

Authors:  B D Lacroix; M O Karlsson; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.